Get the Daily Brief
Latest Biotech News
CMS launches voluntary GLP‑1 payment model: Medicare widens obesity drug access
CMS unveiled a voluntary Medicare payment model designed to expand coverage of GLP‑1 weight‑loss drugs to eligible beneficiaries. The agency framed the program as a cost‑saving pilot intended to...
FDA approves Yartemlea: first approved therapy for a post‑transplant complement complication
The FDA granted approval to Omeros’s complement inhibitor Yartemlea to treat a severe, potentially fatal complication following hematopoietic stem cell transplants. This marks the first approved...
J&J axes eczema drug from $1.25B buy—program dropped after efficacy miss
Johnson & Johnson said its acquired experimental eczema candidate (JNJ‑5939/NM26) failed to meet internal efficacy criteria and the company has discontinued the program. J&J acquired the asset for...
Biohaven’s potassium‑channel drug fails Phase 2—another mid‑stage setback
Biohaven disclosed that its potassium channel–targeting candidate failed to meet primary endpoints in a Phase 2 trial for major depressive disorder, marking a second mid‑stage setback for the...
Smart tumor‑targeted AAVs enable dynamic delivery—vectors respond to tumor microenvironment
Researchers unveiled an intelligent design framework for adeno‑associated virus (AAV) vectors that dynamically respond to the tumor microenvironment (TME). The approach modifies vector properties...
Broad Marburg antibodies discovered—cross‑neutralize Ravn virus too
Scientists reported discovery of a class of potent neutralizing antibodies that target the Marburg virus and cross‑neutralize the closely related Ravn virus. The work, published in npj Viruses,...
SpatialBench... a benchmark to test agents on real spatial biology workflows
A new benchmark called SpatialBench exposes the gap between agent demos and deployable tools by providing 146 verifiable spatial biology analysis problems drawn from real workflows. The suite...
AI detects paroxysmal AF from sinus ECGs—new screening algorithm
Researchers developed AI software that detects paroxysmal atrial fibrillation (PAF) from ECG recordings captured in sinus rhythm, addressing a key diagnostic blind spot. The tool analyzes subtle...
Conformal ultrathin silicon Hall sensors enable early 3D tumor monitoring
A team developed an ultrathin, conformal crystalline‑silicon Hall sensor array designed to monitor three‑dimensional tumor tissues at early stages. Described in npj Flexible Electronics, the...
Targeted protein degradation: mapping health and ecological effects
Researchers published a cross‑disciplinary analysis examining how targeted protein degraders (TPDs) could affect human health and nonhuman species. The paper surveys mechanisms, off‑target...
CMS rolls out voluntary model: Medicare to expand GLP-1 coverage
CMS launched a voluntary payment model designed to expand Medicare coverage of GLP-1 weight-loss drugs, the agency announced. The model lets participating Medicare plans cover GLP-1s under new...
FDA greenlights Yartemlea — first therapy for deadly stem-cell transplant complication
The FDA approved Omeros’s complement-targeting drug Yartemlea for a severe, potentially fatal complication of hematopoietic stem cell transplants, the company announced in regulatory coverage....
J&J cuts bait — ditches $1.25 billion eczema asset
Johnson & Johnson halted development of an experimental eczema drug it acquired for $1.25 billion, the company disclosed, after the candidate failed to meet internal efficacy standards. The...
Biohaven’s potassium channel drug fails Phase 2 — second mid‑stage setback
Biohaven reported that its potassium channel modulator failed a Phase 2 trial in major depressive disorder, marking a second mid‑stage clinical setback for the company’s experimental program. The...
New antibodies... neutralize Marburg and Ravn — broad filovirus candidate emerges
Researchers reported discovery of potent cross‑neutralizing antibodies that target both Marburg virus and the related Ravn virus, with findings published in npj Viruses. The antibodies bind...
Smart AAVs respond to tumors: design framework boosts targeting
Researchers published an intelligent design framework for adeno‑associated virus (AAV) vectors that dynamically respond to tumor microenvironment cues to improve targeting and intratumoral...
New study maps CAR‑T neurotoxicity — safety pathways identified
Recent research advanced understanding of neurotoxicity associated with CAR‑T cell therapies, mapping hemodynamic and cellular events that precede neuroimmune adverse events. The work synthesizes...
SpatialBench: benchmark exposes agents’ demo‑to‑deployment gap
Authors introduced SpatialBench, a suite of 146 verifiable spatial‑biology analysis problems across five platforms and seven task categories, designed to benchmark AI agents on real laboratory...
Nanovaccines for HCC: engineered particles prime liver tumor immunity
Researchers highlighted nanovaccine platforms engineered to stimulate immune responses against hepatocellular carcinoma (HCC), reporting preclinical data that show enhanced antigen presentation...
Targeted protein degradation... raises cross‑species health and ecological questions
A recent review examined targeted protein degradation technologies and their biological impacts across health and species, outlining therapeutic promise alongside ecological and safety...